The Hoffman ALS Clinical Trial Awards Program
Forecasted
The Hoffman ALS Clinical Trial Awards Program supports investigators conducting early-stage trials of ALS therapies and imaging tracers to build evidence for larger studies and improve treatment and care.
Browse similar grants
Funder: ALS Association
Due Dates (Anticipated): November 2026 (Letter of Intent) | February 2027 (Full Proposal, invitation only)
Funding Amounts: Up to $1,000,000 total over 2 or 3 years, including direct and indirect costs
Summary: Supports biomarker-driven phase 1 and phase 2a trials of ALS therapeutics and imaging tracers.
Key Information: The applicant organization must control the intellectual property under development, with an exception for repurposed generic medications.
Description
The ALS Association’s Hoffman ALS Clinical Trial Awards Program supports early- to mid-stage clinical trials that translate promising laboratory science into improved ALS treatment and care. It funds novel or repurposed disease-modifying and symptomatic therapies, as well as imaging tracers. Trials should generate safety, dosing, and biomarker evidence that helps justify larger studies and attract follow-on funding.
The program particularly welcomes approaches targeting TDP-43 and/or protein aggregation. Priorities include a clear biological rationale, strong preclinical evidence, an integrated biomarker strategy, and outcomes appropriate to the trial phase. Development plans should identify go/no-go milestones and a route to subsequent funding and commercialization. Collaboration and open sharing are positively evaluated.
